Fatigue (HP:0012378)
*We have corrected definition and characterization of fatigue from HPO definition according to Long COVID Physio advocacy
*Fatigue is the term used to describe extreme exhaustion. It is not the same as feeling tired after a busy day, because fatigue is not often caused by over-activity or exertion, and it might not be made better by usual rest or sleep. Fatigue can feel like there is no more energy left in the battery, or like an invisible rope is constantly pulling you back. Fatigue can make moving and thinking difficult, impact the ability to participate in social and community life, and negatively affect education or work. Fatigue is the most common symptom reported by people living with Long COVID.
Source: https://longcovid.physio/fatigue
Synonyms: Fatigue, Tired, Tiredness
Comment: Fatigue is distinct from muscle weakness.
Cross References: MSH:D005221, SNOMEDCT_US:248274002, SNOMEDCT_US:84229001, UMLS:C0015672
KEGG Pathway
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | Thyroid cancer | 6.931e-7 | 0.00001135 | 251.55 | 3567.44 |
| 2 | Central carbon metabolism in cancer | 2.843e-8 | 0.000001862 | 201.25 | 3496.91 |
| 3 | Colorectal cancer | 6.560e-8 | 0.000002148 | 161.85 | 2677.02 |
| 4 | Breast cancer | 4.901e-9 | 6.420e-7 | 139.77 | 2674.44 |
| 5 | Endometrial cancer | 0.000002737 | 0.00002988 | 155.34 | 1989.64 |
GO: Biological Process
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | positive regulation of histone H3-K9 acetylation (GO:2000617) | 0.000002248 | 0.0001148 | 1665.58 | 21661.60 |
| 2 | response to indole-3-methanol (GO:0071680) | 0.000002248 | 0.0001148 | 1665.58 | 21661.60 |
| 3 | cellular response to indole-3-methanol (GO:0071681) | 0.000002248 | 0.0001148 | 1665.58 | 21661.60 |
| 4 | positive regulation of histone H3-K4 methylation (GO:0051571) | 4.082e-8 | 0.00001065 | 713.50 | 12139.53 |
| 5 | regulation of histone H3-K4 methylation (GO:0051569) | 8.685e-8 | 0.00001511 | 535.02 | 8698.92 |
GO: Molecular Function
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | I-SMAD binding (GO:0070411) | 0.00001750 | 0.0002458 | 454.07 | 4973.59 |
| 2 | DNA insertion or deletion binding (GO:0032135) | 0.002498 | 0.01717 | 555.17 | 3326.77 |
| 3 | 1-phosphatidylinositol-4-phosphate 3-kinase activity (GO:0035005) | 0.003495 | 0.01748 | 370.07 | 2093.27 |
| 4 | MutSalpha complex binding (GO:0032407) | 0.003495 | 0.01748 | 370.07 | 2093.27 |
| 5 | transmembrane receptor protein kinase activity (GO:0019199) | 0.000003034 | 0.00008344 | 149.87 | 1904.21 |
GO: Cellular Component
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | phosphatidylinositol 3-kinase complex, class I (GO:0097651) | 0.002498 | 0.03497 | 555.17 | 3326.77 |
| 2 | beta-catenin-TCF complex (GO:1990907) | 0.006482 | 0.04538 | 184.98 | 932.06 |
| 3 | intercalated disc (GO:0014704) | 0.01540 | 0.04881 | 73.93 | 308.54 |
| 4 | catenin complex (GO:0016342) | 0.01540 | 0.04881 | 73.93 | 308.54 |
| 5 | basolateral plasma membrane (GO:0016323) | 0.002449 | 0.03497 | 33.29 | 200.15 |
Hub genes predicted as biomarkers & predicted FDA approved drugs
| Hub Genes (ranked) | FDA-Approved Drugs |
| CTNNB1 | FLUORESCEN SODIUM |
| NF1 | TRAMETINIB, BINIMETINIB, COBIMETINIB, DABRAFENIB, VEMURAFENIB |
| SMAD4 | LYSINE, ALECTINIB |
| KRAS | PANITUMUMAB, CETUXIMAB |
| RET | CABOZANTINIB, VANDETANIB |
| PIK3CA | – |
| BRCA1 | – |
| KIT | NILOTINIB, IMATINIB |
| ERBB4 | DACOMITINIB |
| PMS2 | NIVOLUMAB |
